Nomen | Chondroitin sulfate |
Cas numerum | 9007-28-7 |
MOLECULA | C13h21no15s |
Pondus | 463,36854 |
Einecs numerum | 232-696-9 |
Aqua Solubility | SOLUBILIS in aquam |
Pudicitia | XCVIII% |
Repono | Store ad iusto temperatus |
Forma | Pulverem |
Colo | Alba ad off-album |
Stipare | PE lapides sacculi + Aluminium |
Poly-I (2/3) -n-Acyll-II-amino-II-deoxy-III-o-beta-d-glucopyrurosyl-4- (VI) Sulfonyl, D-Galactose; Chondroitinpoly sulfate; Chondroitin sulfates; Chondroiti nsulfuricacid; Chondroitin sulphuric acida; Chonsurid; CSO; (5ξ) -2- (carboxyamino) -2 -Oxy-III-o-β-d-glucopyruronosyl, IV-o-sulfo-α-l-Sulfo-α-Arabum, Hexopyranose
Descriptio
Chondroitinsulfate (CS) est acidic mucopolysaccharide extractum et purificatum ex animali cartilagine TEXTUS. Chondroitin sulfate habet diversas structurae talis ut a, c, d, E, H et K. Chondroitin sulfate in natura est maxime in animali cartilagine et arteriam, cutis, etc, etc. et continetur. In contentus de Piscium cartilagine est valde dives, ut L% ad LX% in PISTRIS os et valde parum in nota TEXTUS.
Nam coronarius atherosclerotic morbo, auctus sanguinem lipids et cholesterol, arteriosclerosis, angina pectoris, myocardial ischemia, myocardial infarctione, etc in aegris coronarius cor morbo.
Pharmacological actio
Rapamycin (Rapa) habet similes latus effectus ad FK506. In multitudine orci iudiciis, ejus latus effectus inventa est ut dose-dependens et reversible, et Rapa at therapeoutios doses non inventum esse significant nephrotoxicity et non est inventa est significant Nephrotoxicity et non invenitur Hyperplasia. Pelagus toxicus et latus effectus includit: capitis, nausea, vertigine, naribus, et iuncturam dolor. Laboratory abnormalities includit: Thombocytopenia, Leukopenia, humilis Hemoglobin, hypertriglyceridemia, hypercholesterolemia, hypertriglycemia, elevatum iecoris enzymes (Sgot, HyelMalemia, Hypomagnesemia, etc. Cum Rapa Administration, et causa inferioris Plasma Phosphate levels est cogitatio est longum differentur phosphate excretion ab transplantatione renibus per Rapa-secundum immunosuppressive Lorem. Sicut alias immunosuppressants, Rapa habet augeri forte infectio, cum nuntiavit tendentia ad augendam Pneumonia maxime, sed eventum alia opportunistic infectiones non significantly diversis a CSA.
Effectus toxicological
Chondroitin sulfate late existit in humana et animal cartilaginem TEXTUS. Medicinae praeparatio maxime continet duo isomers de Chondroitin sulfate et chondroitin sulfate C et contentus de chondroitin sulfate in cartilaginem de animalibus diversis genera et saecula aliter. Eius pharmacological effectus sunt, ut sequitur: Chondroitin sulfate potest removere lipids et lipoproteins in sanguine, remove cholesterol de sanguine vasa circa cor, ne et facies aTherosclerosis acida in cellulis et pingue acida rate of lipids et pingue acida in cellulis. Chondroitin sulfate potest efficaciter ne et facies coronarius cor morbo. Is est anti-atherosclerosis et anti-atherogenic plaque formation effectus in experimentalem arteriosclerosis exempla; auget coronarius ramis vel collateralis circulationem Atherosclerosis et potest accelerare experimentum coronarius arteriosclerosis vel embolismus. Sanitatem, regenerationem et reparatione myocardial necrosis et degeneratum. Potest crescere in biosynthesis celle angelus Ribonucleic acidum (mRNA) et deeoxyribonucleic acidum (DNA) et habet effectum promovendi cellulam metabolism. Humilis anticoagulant operatio. Chondroitin sulfate habet modica anticoagulant effectus, et quisque I mg de chondroitin sulfate est equivalent ad anticoagulant operatio 0.45u de Heparin. Hoc anticoagulant operatio non dependet in Antithrombin III ad ludere eius partes, potest exercere antichoagulant operatio per fibrinogen ratio. Chondroitin sulfate etiam habet anti-inflammatory, accelerated vulnus sanitatem et anti-tumore effectus.